Pricing In ‘Exceptional’ Times: ICER Aims To Shape US Policy For Novel COVID Drugs, Vaccines
US Institute for Clinical and Economic Review lays out options ranging from the status quo (unrestricted pricing) to compulsory licensing and advanced market commitments in a new white paper.
You may also be interested in...
Highly anticipated decision bodes well for pricing of other future treatments for the disease, the US Institute for Clinical and Economic Review suggests.
The use of patent “march-in” rights as a tool to control the price of drugs developed with US federal funding support remains substantially less popular with the government-funded research community than with politicians.
Innovative purchasing model is not designed to solve the problem of high drug costs, experts point out during a recent discussion at the Brookings Institution.